These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 25994754)

  • 1. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Babuty D; Angoulvant D; Lip GY; Fauchier L
    Eur Heart J; 2015 Jul; 36(28):1822-30. PubMed ID: 25994754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
    Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
    JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R2CHADS2 score and thromboembolic events after catheter ablation of atrial fibrillation in comparison with the CHA2DS2-VASc score.
    Chao TF; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Hsieh MH; Chen SA
    Can J Cardiol; 2014 Apr; 30(4):405-12. PubMed ID: 24582725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification.
    Bisson A; Bodin A; Clementy N; Bernard A; Babuty D; Lip GYH; Fauchier L
    Int J Cardiol; 2018 Jun; 260():93-98. PubMed ID: 29540261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Taillandier S; Olesen JB; Lane DA; Lallemand B; Lip GY; Fauchier L
    Int J Cardiol; 2013 Sep; 167(6):2682-7. PubMed ID: 22795403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Fauchier L; Vourc'h P; Andres CR; Taillandier S; Halimi JM; Lip GY
    J Am Coll Cardiol; 2013 May; 61(20):2079-87. PubMed ID: 23524209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation.
    Abumuaileq RR; Abu-Assi E; López-López A; Raposeiras-Roubin S; Rodríguez-Mañero M; Martínez-Sande L; García-Seara J; Fernandez-López XA; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2015 Nov; 15():156. PubMed ID: 26584938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic parameters versus CHA2DS2-VASc score in prediction of overall cardiac events, heart failure, and stroke in non-valvular atrial fibrillation.
    Yang LT; Tsai WC; Su HM
    Cardiol J; 2018; 25(1):60-71. PubMed ID: 28714523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there association between changes in eGFR value and the risk of permanent type of atrial fibrillation? Analysis of valvular and non-valvular atrial fibrillation population.
    Mlodawska E; Tomaszuk-Kazberuk A; Lopatowska P; Bachorzewska-Gajewska H; Malyszko J; Dobrzycki S; Musial WJ
    Kidney Blood Press Res; 2014; 39(6):600-8. PubMed ID: 25531163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHA
    Xing Y; Sun Y; Li H; Tang M; Huang W; Zhang K; Zhang D; Zhang D; Ma Q
    Clin Interv Aging; 2018; 13():497-504. PubMed ID: 29636604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
    Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
    Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.